Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemp-Derived Cannabidiol Extract for Anxiety
NCT06672666Phase 2Active, not recruiting
- Sponsor
- University of Florida
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in anxiety disorder and sleep disorders (2 arms), sponsored by University of Florida. Primary endpoints: Average CBD dose used in the titration phase at 2 weeks, Average CBD dose used in the maintenance phase at 4 weeks and 4 more. Started Jan 2025; status: active, not recruiting.
02
Conditions
anxiety disordersleep disorders
Beyond the preview
Go deeper on NCT06672666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06672666.